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Abstract
Oral mucositis (OM) is a common and often dose-limiting
side effect of cancer therapy. Povidone iodine (PVP-I) formula-
tions have been shown to decrease the incidence and severity of
OM, but the relevance of these findings remains unclear. The
objective of the present study was to review evidence for the use
of PVP-I for OM management. An algorithm identified relevant
articles published online, and a panel of experts with experience in
the management of OM reviewed the findings. Six studies ful-
filled the criteria for full review. Two studies provided evidence of
moderate quality. Two of the studies with negative findings were
confounded by the use of PVP-I concentrations that are too low to
be efficacious. The remaining two studies were found to have
design flaws. There exists reasonable evidence to support a rec-
ommendation for the use of PVP-I in the management of cancer
therapy-related OM. 
Introduction
Oral mucositis (OM) is considered one of the most severe
non-haematological complications of cancer therapy, affecting
more than 40% of patients undergoing some types of chemother-
apy and almost all head and neck cancer patients undergoing
radiotherapy.1,2 The condition is characterized as an inflammatory
process that disrupts the mucous lining of the oral cavity and parts
of the pharynx. Symptoms include oedema, ulceration and bleed-
ing, with patients often having difficulty swallowing or talking.
The associated ulcers and oral lesions that develop can cause sig-
nificant pain, to the extent where patients may be unable to eat
solid food or even ingest liquids at severe stages of OM. In
extreme cases, a more serious form called confluent mucositis can
arise, lining the patient’s mouth and tongue with a white mucus
coating. OM is thought to occur independently of oral mucosal
infections of viral and fungal aetiology, but it may be exacerbated
by such concomitant infections. Therefore, good oral hygiene
practices are emphasized to prevent lesions becoming infected
with pathogenic microbial flora, of which immunosuppressed
patients are likely to be at greater risk.3
Severe OM in patients is a dose-limiting toxicity of cancer
therapy as it can necessitate physicians reducing or omitting
planned interventions.4 In very severe cases, treatment interven-
tions are interrupted and patients may require hospitalization.5,6
Such dosage modifications or the discontinuation of recommend-
ed chemo/radiotherapy regimens can have a negative impact on
clinical outcomes. The development of effective regimens for
severe OM is therefore necessary to improve quality of life and
treatment outcomes for cancer patients.
Due to heterogeneity in study designs relating to differing
aims, methodology and design quality, the evidence available is
conflicting and confusing.7,8 The Journal of the National
Comprehensive Cancer Network (NCCN) published the NCCN
Task Force Report: Prevention and Management of Mucositis in
Cancer Care in 2008, which makes suggestions for good practice
but due to the paucity of strong evidence does not make any rec-
ommendations for the treatment of OM.2
In order to provide clearer guidance for clinicians, the
Multinational Association of Supportive Care in Cancer
(MASCC) in collaboration with the International Society of Oral
Oncology (ISOO) conducted a comprehensive assessment of the
literature to develop evidence-based and consensus-backed OM
clinical practice guidelines.9 The MASCC/ISOO guidelines are
based on evidence from studies looking at interventions used in
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specific cancer treatment regimens.10 For example, benzydamine
is only recommended for head and neck cancer patients receiving
moderate dose radiotherapy (up to 50 Gy) without concomitant
chemotherapy. This is clinically relevant only to a minority of head
and neck cancer patients. However, at least some of the suggested
therapeutic agents may not be available in all markets or affordable
for all patients. A more universal approach to OM management
therefore requires the additional consideration of regulatory and
economic factors at play. 
While a number of antimicrobial mouthwashes are available,
iodophore-based formulations including povidone iodine (PVP-I)
have remained popular as antimicrobial agents. PVP-I formula-
tions have a long track record of safe and effective use for the treat-
ment of antisepsis and wound healing.11 The iodine within PVP-I
forms a complex with the synthetic carrier polymer polyvinyl
pyrrolidine, and in an aqueous medium, free iodine is released.
PVP-I complexes release free iodine into the medium and an equi-
librium is established, with further free iodine molecules released
from PVP-I as iodine-consuming germicidal activity proceeds.
This concentration-dependent equilibrium of free iodine to PVP-
bound iodine helps to address tolerability issues.12 The anti-micro-
bial properties associated with iodine involve the inhibition of crit-
ical cellular mechanisms via the oxidation of nucleotides, amino
acids and fatty acids in cell membranes.13 PVP-I has been shown
to be effective against both gram-negative and gram-positive bac-
teria, yeasts, protozoa and viruses.14 An additional feature of rele-
vance is that there have been no documented cases of bacterial
resistance to iodine, likely due to its multiple mechanisms of
action.15 In vitro evidence suggests that iodine not only has broad-
spectrum antibacterial, antifungal and antiviral effects, but also
anti-inflammatory effects that have been proven to inhibit inflam-
mation arising from the host response.16 These effects have been
shown to be clinically relevant in several conditions.17 For these
reasons, PVP-I formulations are extensively used for surgical site
preparation, wound management, and feminine care.
Although randomized clinical trials using PVP-I oral gargle for
the treatment of OM have been published, the overall implications
of these findings have not been thoroughly addressed. Both posi-
tive and negative data for the use of PVP-I has been found in the
literature. The 2014 MASCC/ISOO guidelines note that studies of
PVP-I oral gargle present inadequate or conflicting data, conclud-
ing with the designation No guideline possible.10 However, con-
cerns have been raised that at least some of the negative findings
reported in the literature may be misleading, as a number of studies
have used final concentrations of oral PVP-I that are well below
the recommended effective concentration. The current review was
undertaken to systematically assess the overall level of evidence
present in the literature regarding PVP-I in the treatment of OM.
Materials and Methods
Literature search
A literature search was conducted to identify clinical OM stud-
ies of satisfactory relevance. Expert panellists were responsible for
reviewing the studies and providing feedback. These panellists are
all listed as co-authors of this report and were selected based on
their experience in managing OM in a multidisciplinary setting.
The method for literature review and assessment was agreed with
the authors at the beginning. We excluded review/systematic
review articles, reports from duplicated publications or follow-up
reports from the same study, clinical practice/chart reviews, in
vitro/in vivo non-clinical studies, and interventions with povidone
iodine as a component of combination treatment, rather than as a
single agent (Table 1 and Figure 1).
Inclusion/exclusion criteria
Inclusion criteria were English language publications reporting
testing of a PVP-I intervention for OM in humans in relation to
cancer, published in a peer-reviewed journal, and indexed in
Medline on or before August 31, 2016. Aspects such as selection
                                Review
Table 1. Inclusion and exclusion criteria for literature search.
Inclusion                                                                                                                      Exclusion 
Povidone iodine (PubMed term)                                                                                                                 Non-clinical trial
Oral mucositis OR stomatitis (PubMed term)                                                                                         Review/systematic review
Cancer OR malignancy OR malignancies (PubMed term)                                                                     Duplicated publication or follow-up report from the same study 
Published in peer-reviewed journal (online-only publications permitted for inclusion)              Practice/chart report
All age groups                                                                                                                                                   In vitro/in vivo non-clinical study
                                                                                                                                                                             Povidone-iodine as part of combination, rather than single agent 
                                                                                                                                                                             Trials involving haematopoietic stem cell transplantation
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Figure 1. Flow diagram of search results. HSCT, hematopoietic
stem cell transplantation; RCT, randomized controlled trials.
                                          [Oncology Reviews 2017; 11:341]                                                            [page 83]
                                                                                                                                Review
of patients, allocation of patients to treatment groups, therapeutic
regimen, study administration, withdrawals from study, patient
blinding (randomized controlled trials only), measurements and
statistical analysis were evaluated. Upon review of the articles pre-
sented, 6 expert panellists (the authors of this review) with exten-
sive experience in the treatment of OM provided their evaluation
of: i) the level (quality) of the evidence in the studies supporting
PVP-I usage for the treatment of OM; and ii) the class (strength) of
recommendation for its usage in OM management (see Addendum
for recommendation criteria).
Results
Of the 23 abstracts initially identified in the Medline search, 6
were selected for in-depth review in accordance with the selection
algorithm. The studies are summarized in Table 2.
Rahn et al. investigated the efficacy of PVP-I for the prophy-
laxis of mucositis during antineoplastic radiochemotherapy.18
Forty patients were randomly assigned to a treatment or control
group, with all receiving prophylaxis of mucositis with nystatin,
dexpanthenol, rutoside and immunoglobulin. In addition, the
patients of the treatment group performed rinsing 4 times daily
with 1% PVP-I, and the control patients with sterile water. The
onset of OM in the control group was at 1.5 weeks from the start
of cancer therapy as opposed to 2.25 weeks in the treatment group.
The mean total duration of mucositis was 2.75 weeks in patients
receiving PVP-I treatment and 9.25 weeks in control patients
(P<0.001), with mean area under the curve (AUC) values of 2.5 in
treatment patients versus 15.75 for the control patients (P<0.001).
Although this study is now somewhat dated as prophylaxis with
nystatin is no longer considered standard, the differences observed
in this trial were both statistically and clinically significant. It was
concluded that rinsing with PVP-I reduced the incidence, time to
onset, severity and duration of oral mucositis during antineoplastic
radiochemotherapy.
Similarly, in a trial by Madan et al., 80 patients with head and
neck cancer undergoing curative radiotherapy were treated with
either 0.12% chlorhexidine, 1% PVP-I or salt/soda mouthwash-
es.19 It was found that patients receiving PVP-I had significantly
lower OM scores compared to both the chlorhexidine and salt/soda
groups after 5 weeks of treatment. It was therefore concluded that
PVP-I could reduce the severity and delay the onset of cancer ther-
apy-related OM.
Yoneda et al. found that a 0.5% solution of PVP-I when includ-
ed as part of an oral hygiene rinse program using a special elec-
tronic dental e-brush with irrigation and suctioning of the mouth
significantly lowered the incidence of OM.20 In addition, the pro-
portion of subjects with newly detected opportunistic pathogens
was higher in the non-special care group, for which the authors
concluded that irrigation with PVP-I is likely to improve patient
quality of life and may reduce hospitalization times. Although the
study concluded that PVP-I is effective for the treatment of OM, it
is important to note that unlike the other five studies, this study
used patients with esophageal cancer (which may not always be
technically classified as a head and neck cancer), which diversifies
the patient user group.
A study by Roopashri et al. compared benzydamine (0.15%),
chlorhexidine (0.2%) and PVP-I (5%), and found evidence of effi-
cacy for all interventions,21 but concluded that benzydamine was
the superior agent. In fact, the incidence of mucositis was not sta-
tistically different in the study and control groups. The observed
differences in severity of mucositis and pain did not meet statistical
significance. However, the authors did not adequately describe the
overall trial design, particularly in relation to blinding. Despite
stating that the mouth-rinsing regimen was under professional
supervision, it was concluded that compliance with benzydamine
was superior. The impact of the findings and the extent of benefit
afforded by PVP-I or other treatments in this study is therefore dif-
ficult to discern.
The study design employed by Hejna et al. tested PVP-I
together with amphotericin B (antiseptic agent group) as the com-
parator for GM-CSF in the prevention and treatment of OM.22 The
author concluded that GM-CSF treatment resulted in delayed onset
and shorter duration of OM. It is noteworthy that the final concen-
tration of PVP-I oral gargle - though not explicitly stated - is sig-
nificantly lower than the current recommended concentration of at
least 1%. The investigators state 4 mL of betaisodina (7.5% PVP-
I) was diluted in 125 mL of water, implying a final concentration
of 0.24%. This concentration represents a less than 1 in 4 dilution
of the recommended strength.
Rao et al. evaluated the efficacy of turmeric in preventing radi-
ation-induced mucositis.23 In a single-blinded, randomized, con-
trolled clinical trial conducted with head and neck cancer patients
requiring 70 Gy of radiation or chemoradiotherapy, patients were
randomly assigned to receive either turmeric gargle or PVP-I as an
active comparator. The study concluded that gargling with turmer-
ic by head and neck cancer patients undergoing radiation therapy
was superior to PVP-I in delaying and reducing the severity of
mucositis. PVP-I was used as a comparator at a final concentration
approximately 10-fold below that which is recommended. It is
therefore likely that the absence of efficacy for PVP-I in this study
was entirely due to its low concentration.
In summary, the 3 studies conducted by Rahn, Madan and
Yoneda found evidence for the efficacy of PVP-I in alleviating the
symptoms of OM. In contrast, the studies by Roopashri, Hejna and
Rao did not support PVP-I usage. However, the study by
Roopashri suffers from a lack of statistically significant findings,
whilst the Hejna and Rao studies used very low concentrations of
PVP-I that explain the lack of efficacy. 
When the expert panelists who reviewed the studies were
asked for their evaluation of the overall level (quality) of evidence
considering the strengths of each study, five responded that there
was moderate-quality evidence from one or more randomized con-
trolled trials, while the remaining panelist indicated that there was
moderate-quality evidence from one or more well-designed, well-
executed nonrandomized studies, observational studies, or registry
studies. Similarly, when asked on the level of recommendation
warranted due to this evidence, one panelist gave a recommenda-
tion of strong, while the remaining five panelists provided a rec-
ommendation of moderate (taking into account the risk/benefit
profile). The slight discrepancy in opinion may have been due to
the different clinical settings and standards familiar to the different
study coauthors (who were all from different countries).
Discussion
The overall objective of the present study was to provide an
objective review of the literature in regards to the use of PVP-I for
the management of OM. We sought to critically evaluate 6 of the
most relevant clinical trials in the literature that used PVP-I gargle
in the treatment or prevention of cancer-related OM, of which the
Rahn, Madan, and Yoneda studies were determined as having pos-
itive evidence. The Hejna and Rao studies showed negative results,
however, this was thought likely to be due to the stated PVP-I con-
centrations being several-fold below that which is recommended.
The study by Roopashri reported only descriptive terms for its
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results, with no statistically significant conclusions. PVP-I gargle
is marketed for oral care at 1% concentration, and it appears that a
common flaw in methodology is its inappropriate dilution during
clinical application to levels that would be non-efficacious. In con-
trast, for the randomized studies with concentrations ranging
between 0.5-1% PVP-I, all three showed the effective alleviation
of OM-related symptoms. The differing conclusions of the studies
may be due to differences in the tumor types, patient populations
and chemo/radiotherapy regimens used. These differences were
not always discernable. For example, the Yoneda study listed the
5-FU regimen used but not the dosage of radiotherapy, while the
Hejna study simply stated, patients who had undergone radiother-
apy of head and neck were eligible, if at least 6 weeks had elapsed
since termination of therapy and the resolution of acute toxic
effects of treatment. In contrast, the Madan and Rao studies used
identical radiation treatment regimens (2 Gy per day, five times a
week without any intended gaps for a planned target dose of 70 Gy
(7 consecutive weeks). It is recommendable for future reports to
list the full details of chemo/radiotherapy regimens used in order
to better determine the causes for distinct findings.
The oral mucosa has a rapid rate of cellular turnover, and is
therefore highly susceptible to cancer treatment-related toxicity
caused by chemotherapy and ionizing radiation.24 Complications
with inflamed tissue can also arise due to the diverse and complex
microflora that colonizes the oral cavity. The effective treatment of
OM therefore likely requires both the inflammatory and microbial
aspects to be addressed.25 As an agent that exhibits potent and clin-
ically relevant anti-inflammatory and antimicrobial properties,14,17
PVP-I formulations could therefore impact the pathophysiological
mechanisms responsible for OM.
Strong mechanistic rationale exists for the application of PVP-
I in treating the symptoms of OM. In vitro and in vivo studies have
revealed potent anti-inflammatory, antiseptic, anti-oedematous,
and anti-hemostatic effects in a wide range of models. The anti-
inflammatory effects of PVP-I on microbial-induced cytokine gen-
eration have been observed in various cell lines, including human
neutrophils. TNF-α is an important mediator of inflammation and
its dysregulation is implicated in various chronic diseases. It was
demonstrated that PVP-I suppresses TNF-α release from human
neutrophils in response to stimulation by Staphylococcus aureus
and Respiratory Syncytial Virus epitopes. Similarly, the enzyme ß-
galactosidase is considered a marker of bacterial activity during
the inflammatory process. Treatment with varying concentrations
of PVP-I has been shown to reduce ß-galactosidase activity in
Escherichia coli cultures and supernatant.26
A position paper released by the European Wound
Management Association (EWMA) notes the broad spectrum of
PVP-I activity against both gram positive and negative bacteria,
fungi, endospores and viruses.26 While evidence of cross-resis-
tance to antiseptics and antibiotics has been documented for many
agents, acquired resistance and cross-resistance has been rarely
reported for iodine when used for specific indications.27 This lack
of resistance is thought to be due to the diverse mechanisms
through which iodine exerts its effects.
PVP-I is also likely to have anti-oedematous effects. A single-
blind randomized study was conducted to evaluate facial swelling
in postoperative patients over varying time intervals. In the treat-
ment group, a 0.5% PVP-I solution at a concentration of 0.5
mg/mL caused a significant reduction in postoperative swelling
compared to the control group (P<0.01). This effect of PVP-I was
suggested to be due to its inhibitory effect on leukotriene B4 and
leukocyte extravasation.28
Further investigation into the anti-hemostatic effects of PVP-I
have similarly revealed important findings. In a study of fresh
bleeding following irrigation of the extraction socket in patients
that have had a tooth removed, 19 of 25 patients in the treatment
group showed spontaneous cessation of bleeding upon application
of PVP-I, which was observed in only 5 of the 25 patients irrigated
with saline. These observations were made prior to drying the
socket with gauze following which the sockets were compressed.
Post-extraction bleeding was determined to be significantly
(P<0.01) controlled by PVP-I treatment as compared to saline.29
The anti-hemostatic effect may help patients with bleeding from
severe mucositis and this needs to be investigated further.
From these findings, it appears that the benefits of PVP-I for
the treatment of inflammatory conditions such as OM could be
broader than its effects as an anti-microbial agent. The long track
record of safe and efficacious use of PVP-I in clinical settings is
also an advantage for further clinical investigation. 
The current options available for OM management in clinical
trials and clinical practice are severely limited. Keefe et al. has
encouraged the pharmaceutical industry to refocus its efforts on
developing such agents in areas of unmet need, including OM and
chemotherapy-induced nausea/vomiting.30 The considerable
unmet medical needs that remain for OM necessitate the investiga-
tion of a wider range of therapies.
The authors suggest that there is moderate scientific evidence
for benefit provided by PVP-I in the management of OM; however,
additional studies are encouraged. The authors also agree that
based on the available evidence, PVP-I can be recommended for
the prevention and treatment of OM.
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